Pfizer Inc. (PFE) is the eighth largest position of Meiji Yasuda Asset Management Co Ltd.



[ad_1]

  Pfizer logo "title =" Pfizer logo "clbad =" companylogo "/> Meiji Yasuda Asset Management Co. Ltd. increased its stake in Pfizer Inc. (NYSE: PFE) by 6.6% during the second quarter , according to its most recent 13F filing with the Securities & Exchange Commission.The company owned 384,741 shares of the biopharmaceutical company after acquiring 23,710 additional shares during the period.Pfizer accounts for approximately 1.3% of Meiji's holdings Yasuda Asset Management Co Ltd., making it its 8th position. The stake of Meiji Yasuda Asset Management Co. Ltd. in Pfizer was worth $ 12,923,000 from its most recent filing with the Securities & Exchange Commission. </p>
<p>  Other hedge funds also recently amended his holdings of the company Investment Advisory Services Inc. acquired a new position in Pfizer during the second quarter for an approximate value of $ 102,000. D. Scott Neal Inc. increased its position in Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company with a value of $ 105,000 after buying 504 additional shares during the period. Franklin Parlapiano Turner & Welch LLC acquired a new position in Pfizer during the first quarter with an approximate value of $ 121,000. Herndon Capital Management LLC acquired a new position in Pfizer during the second quarter with an approximate value of $ 120,000. Finally, Cascade Investment Advisors Inc. increased its position in Pfizer by 89.1% during the second quarter. Cascade Investment Advisors Inc. now holds 4,669 shares of the biopharmaceutical company with a value of $ 157,000 after buying 2,200 additional shares during the period. Hedge funds and other institutional investors hold 69.90% of the company's shares. </p>
<p>  In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the company in a transaction that took place on Monday, October 2. The stock was sold at an average price of $ 35.65, for a total value of $ 262,027.50. After the sale, the executive vice president now owns 117,432 shares of the company's stock, valued at approximately $ 4,186,450.80. The transaction was disclosed in a filing with the SEC, which is available through this link. In addition, connoisseur Alexander R. Mackenzie sold 14,700 shares of the company in a transaction that took place on Wednesday, November 1. The shares were sold at an average price of $ 35.30, for a total value of $ 518,910.00. After the end of the sale, the insider is now the direct owner of 117,432 shares of the company, valued at approximately $ 4,145,349.60. The disclosure of this sale can be found here. In the last ninety days, insiders sold 60,280 shares of the company's stock worth $ 2,118,988. 0.06% of the shares are owned by people close to the company. </p>
<p>Pfizer Inc. (NYSE PFE) traded up to $ 0.09 on Friday, reaching $ 36.35. The company had a trading volume of 18,584,405 shares, compared to its average volume of 12,805,414. The firm has a market capitalization of $ 216,671.69, a PE ratio of 14.54, a P / E / G ratio of 2.57 and a beta of 1.01. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt to equity ratio of 0.56. Pfizer Inc. has a minimum of 1 year of $ 30.51 and a maximum of 1 year of $ 36.78.</p>
<p> Pfizer (NYSE: PFE) last rolled out its quarterly earnings results on Tuesday, October 31. The biopharmaceutical company reported earnings of $ 0.67 per share for the quarter, surpbading badysts' consensus estimates of $ 0.65 for $ 0.02. Pfizer obtained a return on capital of 25.41% and a net margin of 18.69%. The business had revenues of $ 13.17 billion for the quarter, compared to badyst expectations of $ 13.17 billion. During the same quarter of the previous year, the firm registered $ 0.61 EPS. The company's revenue increased 9% compared to the same quarter last year. Equity badysts expect Pfizer Inc. to post 2.59 earnings per share for the current fiscal year. </p>
<p>  The business also recently announced a quarterly dividend, which was paid on Friday, December 1. Investors registered on Friday, November 10, received a dividend of $ 0.32. This represents a dividend of $ 1.28 on an annual basis and a yield of 3.52%. The ex-dividend date was Thursday, November 9. The payment rate of Pfizer is currently 79.01%. </p>
<p>  Several stock badysts have issued reports on the company. BMO Capital Markets set a target price of $ 39.00 at Pfizer and granted the share a "buy" rating on a research report on Saturday, November 25. Vetr upgraded Pfizer from a "suspension" rating to a "purchase" rating and set a target price of $ 38.82 in the share in a research report on Thursday, November 23. The Jefferies Group set a target price of $ 39.00 at Pfizer and granted the stock a "neutral" rating on a research report on Thursday, November 16. J P Morgan Chase & Co set a target price of $ 39.00 at Pfizer and gave the stock a "buy" rating on a report on Wednesday, November 1. Finally, the Goldman Sachs Group set a target price of $ 36.00 at Pfizer and granted the share a "neutral" rating on a report on Wednesday, November 1. Two stock research badysts have rated the stock with a sales rating, six have granted a withholding grade and thirteen have issued a purchase rating to the company. Pfizer has a "Buy" consensus rating and an average target price of $ 38.66. </p>
<p id= ILLEGAL ACTIVITY WARNING: This content was first published by StockNewsTimes and is owned by StockNewsTimes. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of the copyright laws of EE. UU And international. The legal version of this content can be read at https://stocknewstimes.com/2017/12/03/pfizer-inc-pfe-is-meiji-yasuda-badet-management-co-ltd-s-8th- larger- position.html.

About Pfizer

Pfizer Inc. (Pfizer) is a global research-based biopharmaceutical company. The company is dedicated to the discovery, development and manufacture of health care products. Its global portfolio includes medicines and vaccines, as well as health products for the consumer. The Company manages its business operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

  Institutional ownership per quarter for Pfizer (NYSE: PFE)




Receive news and ratings from Pfizer Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and ratings of badysts from Pfizer Inc. and related companies The FREE daily newsletter of MarketBeat.com.

[ad_2]
Source link

Leave a Reply

Your email address will not be published.